NCT03374774 - A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM) | Biotech Hunter

Enrollment

516

Participants

Timeline

Start Date

November 13, 2017

Primary Completion Date

July 4, 2018

Study Completion Date

July 4, 2018

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

BIAsp 30

Participants will receive commercially available BIAsp 30 according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose.

Trial Locations (18)

110017

Novo Nordisk Investigational Site, New Delhi

226005

Novo Nordisk Investigational Site, Lucknow

380054

Novo Nordisk Investigational Site, Ahmedabad

560092

Novo Nordisk Investigational Site, Bangalore

570004

Novo Nordisk Investigational Site, Mysore

585105

Novo Nordisk Investigational Site, Kalaburagi

590010

Novo Nordisk Investigational Site, Belagavi

641009

Novo Nordisk Investigational Site, Coimbatore

641018

Novo Nordisk Investigational Site, Coimbatore

700054

Novo Nordisk Investigational Site, Kolkata

781006

Novo Nordisk Investigational Site, Guwahati

Unknown

Novo Nordisk Investigational Site, Bangalore

Novo Nordisk Investigational Site, Kolhāpur

Novo Nordisk Investigational Site, Nashik

Novo Nordisk Investigational Site, Pune

Novo Nordisk Investigational Site, Lucknow

625 020

Novo Nordisk Investigational Site, Madurai

695 032

Novo Nordisk Investigational Site, Thriruvananthapuram